AC Immune SA
ACIU Real Time Price USDRecent trades of ACIU by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ACIU's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
ACIU Revenue by Segment or Geography
New patents grants
-
Patent Title: Compounds for the treatment or alleviation of disorders associated with tau aggregates Jan. 21, 2025
-
Patent Title: Anti-abeta therapeutic vaccines Jun. 11, 2024
-
Patent Title: Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates Nov. 14, 2023
-
Patent Title: Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates Jun. 27, 2023
-
Patent Title: Method of safe administration of phosphorylated tau peptide vaccine Jun. 27, 2023
-
Patent Title: Bicyclic compounds for diagnosis and therapy Apr. 11, 2023
-
Patent Title: Anti-tau antibodies and methods of use Jan. 17, 2023
-
Patent Title: Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy Dec. 27, 2022
-
Patent Title: Misfolded tdp-43 binding molecules Oct. 11, 2022
-
Patent Title: Anti-tau antibodies and methods of use Aug. 30, 2022
-
Patent Title: Anti-tau antibodies and methods of use Jun. 07, 2022
-
Patent Title: Compositions of phosphorylated tau peptides and uses thereof Sep. 21, 2021
-
Patent Title: Anti-tau antibodies and methods of use Nov. 17, 2020
-
Patent Title: Anti-abeta therapeutic vaccines Nov. 10, 2020
-
Patent Title: Anti-tau antibodies and methods of use Jul. 14, 2020
-
Patent Title: Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins May. 26, 2020
-
Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Dec. 10, 2019
-
Patent Title: Antibodies obtainable using supramolecular constructs May. 22, 2018
-
Patent Title: Vaccine engineering Mar. 22, 2016
-
Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Dec. 29, 2015
-
Patent Title: Method for improving memory in ad patients Jan. 06, 2015
-
Patent Title: 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system Dec. 23, 2014
-
Patent Title: Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins Mar. 18, 2014
-
Patent Title: Methods and compositions comprising supramolecular constructs Mar. 04, 2014
-
Patent Title: Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers Apr. 02, 2013
-
Patent Title: Humanized anti-beta-amyloid antibody Feb. 22, 2011
-
Patent Title: Therapeutic vaccine Oct. 05, 2010
-
Patent Title: Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers Oct. 05, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ACIU
Recent picks made for ACIU stock on CNBC
ETFs with the largest estimated holdings in ACIU
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ACIU stock a Buy, Sell, or Hold?
- What is the price target for $ACIU stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ACIU stock?
- Who owns the most shares of $ACIU stock?
- What funds own $ACIU stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ACIU Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.